Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2 Cho, B. C., Wang, Y., Li, Y., Wu, L., Besse, B., Marmarelis, M. E., Goto, K., Lee, J., Lee, S., Zhang, Y., Neal, J., Curtin, J., Bauml, J. M., Mahoney, J., Trani, L., Knoblauch, R. E., Tomasini, P. ELSEVIER. 2022: S1566
View details for DOI 10.1016/j.annonc.2022.10.359
View details for Web of Science ID 000897943700326